No king without a crown - impact of the nanomaterial-protein corona on nanobiomedicine

被引:97
作者
Docter, Dominic [1 ]
Strieth, Sebastian [1 ]
Westmeier, Dana [1 ]
Hayden, Oliver [2 ]
Gao, Mingyuan [3 ]
Knauer, Shirley K. [4 ]
Stauber, Roland H. [1 ]
机构
[1] Univ Med Ctr Mainz, Dept Nanobiomed, ENT, D-55101 Mainz, Germany
[2] Siemens AG, Corp Technol, D-91058 Erlangen, Germany
[3] Chinese Acad Sci, Inst Chem, Beijing 100190, Peoples R China
[4] Univ Duisburg Essen, CENIDE, Inst Mol Biol, D-45117 Essen, Germany
关键词
bioinformatics; blood system; colloidal chemistry; label-free quantification; mass spectrometry; nanomaterials; nanomedicine; nanotoxicology; proteomics; IN-VIVO; GOLD NANOPARTICLES; SURFACE-PROPERTIES; LIPID-NANOPARTICLES; ADSORBED PROTEINS; PLASMA-PROTEINS; TIME EVOLUTION; PARTICLE-SIZE; NANOMEDICINE; ADSORPTION;
D O I
10.2217/nnm.14.184
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Besides the wide use of nanomaterials in technical products, their application spectrum in biotechnology and biomedicine is steadily increasing. Whereas the physico-chemical properties and behavior of nanomaterials can be engineered and characterized accurately under idealized conditions, this is no longer the case in complex physiological environments. In biological fluids, proteins rapidly bind to nanomaterials forming the protein corona, critically affecting the nanomaterials' biological identity. As the corona impacts in vitro and/or in vivo nanomaterial applications, we here review the concept of the protein corona and its analytical dissection. We comment on how corona signatures may be linked to effects at the nano-bio interface and conclude how such knowledge is offering novel opportunities for improved nanomedicine.
引用
收藏
页码:503 / 519
页数:17
相关论文
共 116 条
[1]   Nanomaterial standards for efficacy and toxicity assessment [J].
Adiseshaiah, Pavan P. ;
Hall, Jennifer B. ;
McNeil, Scott E. .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2010, 2 (01) :99-112
[2]   Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy [J].
Aggarwal, Parag ;
Hall, Jennifer B. ;
McLeland, Christopher B. ;
Dobrovolskaia, Marina A. ;
McNeil, Scott E. .
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (06) :428-437
[3]   The Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in Plasma and Serum [J].
Anderson, N. Leigh .
CLINICAL CHEMISTRY, 2010, 56 (02) :177-185
[4]   Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells [J].
AshaRani, P. V. ;
Mun, Grace Low Kah ;
Hande, Manoor Prakash ;
Valiyaveettil, Suresh .
ACS NANO, 2009, 3 (02) :279-290
[5]   Fabricated Micro-Nano Devices for In vivo and In vitro Biomedical Applications [J].
Barkam, Swetha ;
Saraf, Shashank ;
Seal, Sudipta .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2013, 5 (06) :544-568
[6]   Environmental challenges for nanomedicine [J].
Baun, Anders ;
Hansen, Steffert Foss .
NANOMEDICINE, 2008, 3 (05) :605-608
[7]   Regulating Nanomedicine - Can the FDA Handle It? [J].
Bawa, Raj .
CURRENT DRUG DELIVERY, 2011, 8 (03) :227-234
[8]   Analytical Methods for Characterizing the Nanoparticle-Protein Corona [J].
Capriotti, Anna Laura ;
Caracciolo, Giulio ;
Cavaliere, Chiara ;
Colapicchioni, Valentina ;
Piovesana, Susy ;
Pozzi, Daniela ;
Lagana, Aldo .
CHROMATOGRAPHIA, 2014, 77 (11-12) :755-769
[9]   Evolution of the Protein Corona of Lipid Gene Vectors as a Function of Plasma Concentration [J].
Caracciolo, Giulio ;
Pozzi, Daniela ;
Capriotti, Anna Laura ;
Cavaliere, Chiara ;
Foglia, Patrizia ;
Amenitsch, Heinz ;
Lagana, Aldo .
LANGMUIR, 2011, 27 (24) :15048-15053
[10]   Time Evolution of the Nanoparticle Protein Corona [J].
Casals, Eudald ;
Pfaller, Tobias ;
Duschl, Albert ;
Oostingh, Gertie Janneke ;
Puntes, Victor .
ACS NANO, 2010, 4 (07) :3623-3632